Sandra Milligan, a director at Gossamer Bio, Inc. ($GOSS), made one open market purchase of shares in the last year, totaling $50,016. Her latest buy occurred on August 19, 2025. This places her 2,989th out of 4,983 insiders by purchase value, well below the average of $1.46 million over about 3.3 transactions. She reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 19, 2025 | Gossamer Bio, Inc. | $GOSS | Milligan Sandra | Director | P | Common Stock | 26050 | $1.92 | 58,050.0000 | 227,221,261 | 81.41% | 0.01% |
| June 25, 2025 | Gossamer Bio, Inc. | $GOSS | Milligan Sandra | Director | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 227,221,261 | 9999.99% | 0.05% |
| May 29, 2025 | Spyre Therapeutics, Inc. | $SYRE | Milligan Sandra | Director | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 60,275,561 | 9999.99% | 0.04% |
| Jan. 8, 2025 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | Interim CEO | F | Common Stock | 6356 | $0.70 | 13,644.0000 | 0 | 31.78% | 0.00% |
| Dec. 31, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | Interim CEO | M | Common Stock | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 31, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | Interim CEO | M | Restricted Stock Units | 20000 | $0.00 | 0.0000 | 0 | 0.00% | 0.00% |
| Dec. 31, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | Interim CEO & President | M | Restricted Stock Units | 20000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 31, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | Interim CEO & President | M | Common Stock | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 12, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | President | A | Stock option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Oct. 28, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | President | A | Restricted Stock Units | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2024 | Gossamer Bio, Inc. | $GOSS | Milligan Sandra | Director | A | Non-qualified stock option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| May 14, 2024 | Spyre Therapeutics, Inc. | $SYRE | Milligan Sandra | Not found | A | Stock Option (Right to Buy) | 21980 | $0.00 | 21,980.0000 | 0 | 9999.99% | 0.00% |
| May 3, 2024 | Aspira Women's Health Inc. | $AWHL | Milligan Sandra | President | A | EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 15, 2023 | Gossamer Bio, Inc. | $GOSS | Milligan Sandra | Director | P | Common Stock | 32000 | $0.79 | 32,000.0000 | 0 | 9999.99% | 0.00% |
| June 8, 2023 | Gossamer Bio, Inc. | $GOSS | Milligan Sandra | Director | A | Stock Option (Right to Buy) | 35000 | $0.00 | 35,000.0000 | 0 | 9999.99% | 0.00% |
| May 4, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Common Stock | 4984 | $0.00 | 30,767.0000 | 255,169,000 | 19.33% | 0.00% |
| May 4, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | F | Common Stock | 2168 | $24.24 | 28,599.0000 | 255,169,000 | 7.05% | 0.00% |
| May 4, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Restricted Stock Units | 4984 | $0.00 | 4,984.0000 | 255,169,000 | 50.00% | 0.00% |
| May 1, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Restricted Stock Units | 1899 | $0.00 | 0.0000 | 255,169,000 | 100.00% | 0.00% |
| May 1, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Common Stock | 1899 | $0.00 | 26,609.0000 | 255,169,000 | 7.69% | 0.00% |
| May 1, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | F | Common Stock | 826 | $24.63 | 25,783.0000 | 255,169,000 | 3.10% | 0.00% |
| March 31, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | F | Common Stock | 2115 | $23.09 | 24,710.0000 | 255,169,000 | 7.88% | 0.00% |
| March 31, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Common Stock | 5964 | $0.00 | 26,825.0000 | 255,169,000 | 28.59% | 0.00% |
| March 31, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Restricted Stock Units | 5964 | $0.00 | 11,928.0000 | 255,169,000 | 33.33% | 0.00% |
| March 31, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | A | Restricted Stock Units | 29230 | $0.00 | 29,230.0000 | 255,169,000 | 9999.99% | 0.01% |
| March 31, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | A | Stock Option (right to buy) | 104961 | $0.00 | 104,961.0000 | 255,169,000 | 9999.99% | 0.04% |
| Feb. 28, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Restricted Stock Units | 7976 | $0.00 | 0.0000 | 255,169,000 | 100.00% | 0.00% |
| Feb. 28, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | F | Common Stock | 2346 | $25.09 | 20,861.0000 | 255,169,000 | 10.11% | 0.00% |
| Feb. 28, 2023 | Organon & Co. | $OGN | Milligan Sandra | Head of Research & Development | M | Common Stock | 7976 | $0.00 | 23,207.0000 | 255,169,000 | 52.37% | 0.00% |